Danny Federico
ECB Publishing, Inc.
Perrigo Company, plc has announced a voluntary recall of 16,500 cans of its store-brand Premium Infant Formula with Iron Milk-Based Powder. The recall, affecting three specific lot codes, was initiated after routine testing revealed Vitamin D levels in the formula that exceeded the maximum permissible limit. The affected products were distributed to H-E-B Grocery Company, LP, in Texas and to CVS locations in California, Florida, Indiana, Michigan, Missouri, New Jersey, Pennsylvania, Rhode Island, South Carolina, Tennessee, Texas and Virginia. This recall does not impact other products or retailers.
The recall was conducted in consultation with the U.S. Food and Drug Administration (FDA). Perrigo has confirmed that no adverse events have been reported thus far in connection with the elevated Vitamin D levels in the recalled products.
According to Perrigo, the majority of infants who have consumed the affected formulas are unlikely to experience any adverse health effects. However, the company cautions that a small subset of infants with specific vulnerabilities, such as impaired renal function, could potentially face health complications from the elevated Vitamin D levels. Parents and caregivers are advised to check the lot codes on the bottom of the packaging to determine if they have purchased the recalled product. If any concerns arise, they are encouraged to consult with their healthcare provider.
The recalled lot codes are as follows:
Product shipped to CVS starting Feb. 6, 2024:
Lot code: T11LMYC – USE BY 11NOV2025
(Material: 975261, UPC: 050428318034)
Product shipped to H-E-B Grocery Company, LP, starting Feb. 2, 2024:
Lot code: T11LMXC – USE BY 11NOV2025
Lot code: T09LMXC – USE BY 09NOV2025
(Material: 788362, UPC: 041220164578)
Perrigo has notified H-E-B and CVS and requested that they inspect their retail and warehouse inventories and isolate any impacted products.
Consumers who have purchased the recalled formulas are urged to contact Perrigo Consumer Affairs at 1 (800) 538-9543 for more information. Additionally, any adverse symptoms observed in infants using the product should be reported to the FDA's MedWatch Adverse Event Reporting program at www.fda.gov/medwatch/report.htm.